DIM-Journal Club: EBM 27 Mai 2014 08:20 Ort: Konferenzzimmer Haus 01/U142 Referent: Marino Quarella Week 48 results of a randomized, open label trial – Switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus continuation of non-nucleoside reverse transcriptase inhibitor plus emtricitabine/tenofovir disoproxil fumarate in virologically suppressed HIV subjects